Completed PHASE1 INTERVENTIONAL 3-arm NCT02512575

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.

Sponsor: AstraZeneca

Conditions Healthy Subjects Pharmacodynamics Pharmacokinetics Rheumatoid Arthritis Safety Tolerability

Interventions AZD9567 Monohydrat Placebo oral suspension/ Placebo capsule Prednisolone

Updated 8 times since 2017 Last updated: Sep 27, 2018 Started: Nov 18, 2015 Primary completion: Sep 26, 2016 Completion: Sep 26, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Subjects and Pharmacodynamics and is currently completed. AstraZeneca leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Nov 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany